PPT-MRD in myeloma

UKMF Spring Day Assessment of disease response CR and beyond Roger Owen St Jamess Institute of Oncology Leeds UK Myeloma trials the challenges What do we need Flow cytometry in MM. Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Ready for Prime Time?. DANA-FARBER . CANCER INSTITUTE. Nikhil C. Munshi, MD . Professor of Medicine . Harvard Medical School. Boston VA Healthcare System. Director . Basic and Correlative Sciences. Dana-Farber Cancer . Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Copenhagen. , . June 11. th. . 2016. EU Drug Approval and Reimbursement Policy. No standardized. cost-benefit formula exists across the EU. . The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) . Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. cyclin. and PI3k pathways. UKMF Spring meeting 2015. Kwee Yong, UCL Cancer Institute. Not one, but many myelomas. Dysregulation. of D-type . cyclin. in multiple myeloma. Early oncogenic events . dysregulate. H . Nèji. , H . Abid. , A . Mâalej. , S . Haddar. , R . Akrout. *, . M . Ezzeddine. *, S . Baklouti. *, . Z . Mnif. **, J . Mnif. Imaging department . Habib. . Bourguiba. Hospital, . *Rheumatology department . Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT.